A carregar...
Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
BACKGROUND: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m(2)) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent...
Na minha lista:
| Publicado no: | South Asian J Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Medknow Publications & Media Pvt Ltd
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5506812/ https://ncbi.nlm.nih.gov/pubmed/28702409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2278-330X.208840 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|